Salvatore Gueli Alletti1, Cristiano Rossitto2, Stefano Cianci3, Stefano Restaino4, Barbara Costantini2, Francesco Fanfani5, Anna Fagotti6, Francesco Cosentino2, Giovanni Scambia2. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy. Electronic address: gueliallettis@gmail.com. 2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy. 3. Department of General Surgery and Medical Surgical Specialties, Gynecologic Clinic, University of Catania, Catania, Italy. 4. Institute for Maternal and Child Health-IRCCS Burlo Garofolo, University of Trieste, Trieste, Italy. 5. Department of Medicine and Aging Sciences, G. D'Annunzio University of Chieti-Pescara, Chieti and Pescara, Italy. 6. Division of Minimally Invasive Gynecology, St. Maria Hospital, University of Perugia, Terni, Italy.
Abstract
STUDY OBJECTIVE: To compare the surgical and clinical outcomes of patients affected by early-stage endometrial cancer treated using the Telelap ALF-X platform versus conventional laparoscopic surgery. DESIGN: Single institution retrospective cohort study (Canadian Task Force classification II-2). SETTING: Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy. PATIENTS: The study involved 89 patients affected by early-stage endometrial cancer who underwent elective surgical staging between October 2013 and September 2014. Among them, 43 (48.3%) underwent Telelap ALF-X staging (ALF-X group), and 46 (51.7%) underwent conventional laparoscopic staging (laparoscopic group). INTERVENTIONS: All selected patients underwent laparoscopic staging with radical hysterectomy (class A sec Querleu-Morrow), bilateral salpingo-oophorectomy, and pelvic lymphadenectomy if required. The 2 surgical groups were further divided into patients who did not require pelvic lymphadenectomy (subgroup 1) and those who underwent pelvic lymphadenectomy (subgroup 2). MEASUREMENTS AND MAIN RESULTS: In the ALF-X group, the median operative time was 128 minutes (range, 69-260 minutes) for subgroup 1 and 193 minutes (range, 129-290 minutes) for subgroup 2. In the laparoscopic group, the median operative time was 82 minutes (range, 25-180 minutes) in subgroup 1 and 104 minutes (range, 36-160 minutes) in subgroup 2. The difference in operative time between subgroups was statistically significant in both the ALF-X and laparoscopic groups (p = .000). In subgroup 1 of the ALF-X group, there was 1 conversion to standard laparoscopy (2.3%) and 2 conversions to laparotomy (4.7%) (p = .234). No conversions to laparotomy occurred in the laparoscopic group. Postoperative complications included 1 case of pelvic hematoma (2.3%) in subgroup 1 of the ALF-X group and 1 case of subocclusion and 1 case of pulmonary edema (4.3%) in subgroup 1 of the laparoscopic group. CONCLUSION: Based on operative outcomes and complication rates, our results suggest that the Telelap ALF-X approach is feasible and safe for endometrial cancer staging; however, further studies are needed to definitively assess the role of Telelap ALF-X early-stage endometrial cancer staging.
STUDY OBJECTIVE: To compare the surgical and clinical outcomes of patients affected by early-stage endometrial cancer treated using the Telelap ALF-X platform versus conventional laparoscopic surgery. DESIGN: Single institution retrospective cohort study (Canadian Task Force classification II-2). SETTING: Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy. PATIENTS: The study involved 89 patients affected by early-stage endometrial cancer who underwent elective surgical staging between October 2013 and September 2014. Among them, 43 (48.3%) underwent Telelap ALF-X staging (ALF-X group), and 46 (51.7%) underwent conventional laparoscopic staging (laparoscopic group). INTERVENTIONS: All selected patients underwent laparoscopic staging with radical hysterectomy (class A sec Querleu-Morrow), bilateral salpingo-oophorectomy, and pelvic lymphadenectomy if required. The 2 surgical groups were further divided into patients who did not require pelvic lymphadenectomy (subgroup 1) and those who underwent pelvic lymphadenectomy (subgroup 2). MEASUREMENTS AND MAIN RESULTS: In the ALF-X group, the median operative time was 128 minutes (range, 69-260 minutes) for subgroup 1 and 193 minutes (range, 129-290 minutes) for subgroup 2. In the laparoscopic group, the median operative time was 82 minutes (range, 25-180 minutes) in subgroup 1 and 104 minutes (range, 36-160 minutes) in subgroup 2. The difference in operative time between subgroups was statistically significant in both the ALF-X and laparoscopic groups (p = .000). In subgroup 1 of the ALF-X group, there was 1 conversion to standard laparoscopy (2.3%) and 2 conversions to laparotomy (4.7%) (p = .234). No conversions to laparotomy occurred in the laparoscopic group. Postoperative complications included 1 case of pelvic hematoma (2.3%) in subgroup 1 of the ALF-X group and 1 case of subocclusion and 1 case of pulmonary edema (4.3%) in subgroup 1 of the laparoscopic group. CONCLUSION: Based on operative outcomes and complication rates, our results suggest that the Telelap ALF-X approach is feasible and safe for endometrial cancer staging; however, further studies are needed to definitively assess the role of Telelap ALF-X early-stage endometrial cancer staging.
Authors: S Cianci; A Rosati; V Rumolo; S Gueli Alletti; V Gallotta; L C Turco; G Corrado; G Vizzielli; A Fagotti; F Fanfani; G Scambia; S Uccella Journal: World J Surg Date: 2019-10 Impact factor: 3.352
Authors: Salvatore Gueli Alletti; C Rossitto; S Cianci; E Perrone; S Pizzacalla; G Monterossi; G Vizzielli; S Gidaro; G Scambia Journal: J Robot Surg Date: 2017-06-17
Authors: Stefano Cianci; Giuseppe Vizzielli; Anna Fagotti; Fabio Pacelli; Andrea Di Giorgio; Alessandro Tropea; Antonio Biondi; Giovanni Scambia Journal: Updates Surg Date: 2018-06-25
Authors: Giuseppe Scaletta; Lorena Quagliozzi; Stefano Cianci; Virginia Vargiu; Maria Cristina Mele; Giovanni Scambia; Anna Fagotti Journal: Updates Surg Date: 2019-04-20
Authors: Vito Andrea Capozzi; Andrea Rosati; Stefano Uccella; Gaetano Riemma; Mattia Tarascio; Marco Torella; Pasquale De Franciscis; Nicola Colacurci; Stefano Cianci Journal: Transl Cancer Res Date: 2020-12 Impact factor: 1.241